ArticleTropical medicine and health2025
Prevalence of chikungunya virus infection in Sabah, Malaysia during 2017-2020.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChikungunya virus (CHIKV) is a mosquito-borne alphavirus and an emerging global health threat. Most research on CHIKV in Malaysia has primarily focused on Peninsular Malaysia, with limited data on its distribution in the endemic regions of Borneo, particularly Sabah. This study aimed to determine the prevalence of CHIKV infection in Sabah, Malaysia.
methodsA total of 130 serum samples, comprising 74 from febrile patients and 56 healthy individuals were collected between 2017 and 2018. Subsequently, 188 serum samples were obtained from febrile patients in Sabah, Malaysia during 2019-2020. All samples underwent quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR) for the detection of the CHIKV genome. Additionally, serological tests were conducted to identify anti-CHIKV IgM and IgG antibodies. Serologically positive samples were further validated using neutralization assays to confirm the presence of CHIKV-specific antibodies.
resultsIn 2017-2018, 16 out of 130 samples (12.3%) tested positive for recent CHIKV infections based on CHIKV RT-qPCR or anti-CHIKV IgM results, while in 2019-2020, 7 out of 188 samples (3.7%) showed recent infections. Among the 16 recent CHIKV-positive cases in 2017-2018, four were asymptomatic individuals. In 2017-2018, 24 (18.4%) individuals tested positive for anti-CHIKV IgG, with 15 (11.5%) showing positive neutralization test results. In 2019-2020, 20 (10.6%) febrile patients were seropositive for anti-CHIKV IgG, with 17 (9.0%) showing CHIKV neutralization positivity. The CHIKV infection rate in Sabah was higher during 2017-2018 compared to 2019-2020.
conclusionsTo the best of our knowledge, this is the first report confirming the presence of CHIKV in both patients and healthy individuals in Sabah using RT-qPCR and neutralization tests. Although the likelihood of transmission from asymptomatic individuals is low, they still present a considerable public health risk. Our results indicate that both basic scientists and clinicians should consider CHIKV when diagnosing febrile patients, and policymakers should put in place effective surveillance and control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.